Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zocor Rx Growth Picks Up In June; Merck Hopes Crestor Helps Revive Market

Executive Summary

Zocor prescriptions appear to be picking up after a difficult first half for Merck's cholesterol lowering agent

You may also be interested in...



Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small

GlaxoSmithKline's levitating act in the third quarter shows that co-promotion deals have kept their magic for the company

Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small

GlaxoSmithKline's levitating act in the third quarter shows that co-promotion deals have kept their magic for the company

California Health Plans Promoting Generics Versus Brand Statins, COX-2s

Four California health plans are mailing $10 coupons to physicians to cover the copay for a new prescription for one of 12 drugs available under the Generic Advantage program

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel